Pediatrix Medical Group Inc "Q&A Our Way: Solid Pricing Growth More than..."

研报英文原文证据摘录

Pediatrix Medical Group Inc "Q&A Our Way: Solid Pricing Growth More than..."

growth in a given quarter, and was near the lower end in 1Q. Hospital admin fees remain

a positive, though management noted longer-term uncertainty as hospital financial

pressure persists. Some admin fee increases are also tied directly to market based wage

increases, which means the impact can be offset by higher practice level salaries. Payer

mix held up better than some feared, though management continues to closely watch

payer mix for any evolving trends.

Valuation: PT to $25

We raise our price target to $25 (prev. $22) which is based on a ~7.0x (prev. 6.5x) EV/

EBITDA multiple applied to our 2027 adj. EBITDA estimate. We raise our multiple to

account for continued positive trends in same unit revenue growth in the business. We

raise our 2026 adj. EBITDA estimate to $291 mln (prev. $288 mln) and our 2027 adj.

EBITDA estimate to $294 mln (prev. $291 mln) to reflect the beat in the quarter.

Highlights from Management Q&A

We had a post quarterly conference call discussion with MD management to review

quarterly results, 2026 guidance, and broader industry trends. In the text below, we list

questions and the company’s responses. The answers are not verbatim, but we put the

company’s answers in their proper context in a give-and-take format.

1Q26 Results

The company reported 1Q revenue of $476 mln and adj. EBITDA of $58 mln,

both ahead of consensus. How did these numbers compare to internal

expectations?

1Q results came in ahead of expectations. Ahead of the quarter, management had

anticipated about 17-19% of full year adj. EBITDA (at the midpoint of guidance) in the

first quarter. This came in closer to 20%. Management noted that non-same unit activity